Takeda Says Rebates, Subsidies Cut $885M IBS Drug Verdict
By Bryan Koenig · August 5, 2026, 7:55 PM EDT
Takeda Pharmaceuticals battled with a class of health plans over whether a Massachusetts federal jury's $885 million antitrust verdict against the drugmaker for conspiring to delay generic competition to anticonstipation drug...
To view the full article, register now.